Durvalumab vs Metformin

Durvalumab vs Metformin: Overview

This comparison examines the pharmacological differences between Durvalumab and Metformin.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Metformin: Activates AMP-activated protein kinase, decreasing hepatic glucose production.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Metformin — 4-9 hours.

Chemical Properties

Molecular Formula: Metformin — C4H11N5.

Molecular Weight: Metformin — 129.1640 g/mol.

Type: Durvalumab — Antibody; Metformin — Small molecule.